Abbvie Deutschland Gmbh and Co Kg

Abbott Gmbh & Co Kg

Abbvie Inc.

Abbott Laboratories Corporation

Wilfried Martin Braje

Liliane Unger

Andreas Haupt

Karla Drescher

Sean Colm Turner

Wilfried Lubisch

Wilfried Hornberger

Wolfgang Wernet

Roland Grandel

Thorsten K Oost

Udo Lange

Hervé Geneste

Herve Geneste

Mario Mezler

Astrid Netz

Margaretha Henrica Maria Bakker

Stevan Wakefield Djuric

Irini Akritopoulou-Zanze

Ana-Lucia Relo

Ana Lucia Relo

Helmut Mack

Karsten M Wicke

Gisela Backfisch

Wilhelm Amberg

Frauke Pohlki

Katja Jantos

Daryl Richard Sauer

Ying Wang

Jason T Brewer

Min Zhang

Andreas Kling

Charles W Hutchins

Berthold Behl

Michael Ochse

Alan Frank Gasiecki

Shashank Shekhar

Noel S Wilson

Hongyu H Zhao

Dennie S Welch

Albert Wayne Kruger

Gerd Steiner

Justin D Dietrich

Marcel Van Gaalen

Thomas Subkowski

Dorothea Starck

Reinhold Mueller

Loic Laplanche

Matthias Mayrer

Viktor Lakics

Hannes Koolman

Christophe Henry

Bhadra Shelat

Carolin Hoft

Jorge Gandarilla

Armin Beyerbach

Huanqiu Li

Christina M Thompson

Anton Bespalov

Jayne Froggett

Ana Lucia Jongen-Relo

Günter Blaich

Anais Jolit

Johannes Kaschel

Johanna Klee

Tanja Lindner

Raimund Peter

Anna Linsenmeier

Thomas Erhard

Katarina Britze

Xiaona Zhao

Andrea Hager-Wernet, Legal Representative

Alfred Hahn, Legal Representative

Silke Weber

Lynette Smyth

Hans-Jürgen Teschendorf

John Darbyshire

Ruxu Xu

Hervè Geneste

Thomas Schultz

Dan Plata

Jincheng Wang

Claudia Krack

Margaretha Henrica Bakker

Rolan Grandel

Hongyu Zhao

Anna Reingruber

Shashank Shekar

The present invention relates to a method of carrying out an organic reaction in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose.

Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose

The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HTreceptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HTreceptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HTreceptor.

Tricyclic quinoline and quinoxaline derivatives

The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I) wherein R, R, R, R, R, A, Y, Y, and Yare as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Modulators of 5-HT receptors and methods of use thereof

The present application relates to 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine, 2,3,4,4a,5,6,7,11b-octahydro-1H-pyrido[3,4-d][2]benzazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1]benzazepine, 1,2,3,4,4a,5-hexahydro-7H-pyrazino[1,2-a][4,1]benzoxazepine, and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[2,1-d][1,5]benzoxazepine, and 5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine derivatives of formula (I) wherein R, R, R, R, R, R, X, X, X, X, Y, Y, and Yare as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

The present invention relates to novel fused heterocyclic or carbocyclic compounds of formula I wherein the variables are as defined in the claims and the description. The invention further relates to pharmaceutical compositions comprising these compounds, and to their use for the treatment of vasopressin-related disorders.

Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases

The present invention relates to compound of formula (I) as tricyclic hexahydrodiazepinoquinolines carrying a cyclic substituent, useful for modulating the 5-HTreceptor and preventing and/or treating conditions and disorders that respond to the modulation of the 5-HTreceptor. The present invention also relates to methods for producing compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for preventing or treating conditions and disorders that respond to the modulation of the 5-HTreceptor by administering compounds of formula (1) or pharmaceutical compositions thereof.

Substituted [1,4]diazepino[6,7,1-ij]quinolines as serotonin 5-HT2C receptor modulators

The present invention relates to tricyclic hexahydrodiazepinoquinolines, such as compounds of formula (I), carrying a substituted alkyl radical, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HTreceptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HTreceptor, to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HTreceptor, and processes for preparing such compounds and compositions. 

Hexahydrodiazepinoquinolines carrying a substituted alkyl radical

The present invention relates to novel substituted oxindole derivatives of formula I wherein the variables are as defined in the claims and the description. The invention further relates to pharmaceutical compositions comprising compounds I and their use for the treatment of vasopressin-related disorders.

Oxindole compounds carrying a CO-bound spiro substituent and use thereof for treating vasopressin-related diseases

The present invention relates to novel 5,6-disubstituted oxindole derivatives and pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising such derivatives, and to the use of such derivatives for the manufacture of a medicament, and methods of treating disorders in a subject in need thereof, such as vasopressin-dependent disorders, using 5,6-disubstituted oxindole derivatives.

5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressin-dependent diseases

The present invention relates to novel carbamate-substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-dependent disorders.

Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases

The present invention relates to novel amidomethyl-substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-dependent disorders.

Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses

The present invention relates to heterocyclic compounds which are positive modulators of metabotropic glutamate receptor. The present invention also relates to the use of these compounds for preparing a pharmaceutical composition and to a method of treating a medical disorder, selected from neurological and psychiatric disorders associated with glutamate dysfunction.

Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor)

The present invention relates to novel substituted oxindole derivatives of the formula (I), pharmaceutical agents containing said derivatives, and the use thereof for the treatment of vasopressin-dependent illnesses.

Substituted oxindole-derivatives and the use thereof for the treatment of vasopressin-dependent illnesses

Growing community of inventors

Rinteln, Germany

Wilfried Martin Braje